Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Impact of Bariatric Surgeries on the Obesity Pharmaceutical Market

Published by: Decision Resources

Published: Apr. 21, 2005 - 18 Pages

The price of this report has been reduced due to its age. The original price was $1,900 for PDF E-mail From Publisher.

Table of Contents


A Changing View of Obesity and Anti-Obesity Therapy

Obesity: Why Is It a Disease?

Treatment of Obesity in the United States

Overview of Bariatric Surgeries

The U.S. Obesity Market




Table 1. Comparison of Select Pharmaceutical Agents for the Treatment of Obesity

Table 2. Types of Bariatric Surgeries




Figure 1. Treatment of Obesity

Figure 2. Growth of the Obesity Population, 1999-2003

Figure 3. Growth in Obesity Prescriptions and Drug Sales, 1999-2003

Figure 4. Growth in Number of Bariatric Surgeries, 1999-2003

Abstract

For morbidly obese patients, bariatric surgery is an increasingly attractive option after more traditional weight loss methods have failed. The lack of long-term efficacy and the modest weight loss associated with currently marketed anti-obesity drugs—particularly among morbidly obese patients—do not make them an attractive therapeutic option. As a result, drug prescriptions have declined over the past few years, and the number of annual bariatric surgeries has risen. The issue for pharmaceutical companies is how this growing recognition of bariatric surgery will affect the market for anti-obesity drugs. This report reviews major considerations in the treatment of obesity, including its classification as a disease, and where pharmaceuticals and bariatric surgery fit into the therapeutic algorithm in the United States. We provide an overview of bariatric surgeries, and we discuss promising emerging therapies in the treatment of obesity and the impact we expect bariatric surgery to have on the overall pharmaceutical market in light of the expected launch of Sanofi-Aventis’s rimonabant (Acomplia).

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009